FI935898A0 - Foerfarande foer stimulering av immunologiskt gensvar - Google Patents

Foerfarande foer stimulering av immunologiskt gensvar

Info

Publication number
FI935898A0
FI935898A0 FI935898A FI935898A FI935898A0 FI 935898 A0 FI935898 A0 FI 935898A0 FI 935898 A FI935898 A FI 935898A FI 935898 A FI935898 A FI 935898A FI 935898 A0 FI935898 A0 FI 935898A0
Authority
FI
Finland
Prior art keywords
foer
stimulation
immunological means
igf
immunological
Prior art date
Application number
FI935898A
Other languages
English (en)
Finnish (fi)
Other versions
FI935898A (fi
Inventor
Ross G Clark
Paula M Jardieu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI935898A0 publication Critical patent/FI935898A0/fi
Publication of FI935898A publication Critical patent/FI935898A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Vessels, Lead-In Wires, Accessory Apparatuses For Cathode-Ray Tubes (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI935898A 1991-06-28 1993-12-28 Foerfarande foer stimulering av immunologiskt gensvar FI935898A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/722,813 US5202119A (en) 1991-06-28 1991-06-28 Method of stimulating immune response
PCT/US1992/005189 WO1993000110A1 (en) 1991-06-28 1992-06-16 Method of stimulating immune response

Publications (2)

Publication Number Publication Date
FI935898A0 true FI935898A0 (fi) 1993-12-28
FI935898A FI935898A (fi) 1993-12-28

Family

ID=24903495

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935898A FI935898A (fi) 1991-06-28 1993-12-28 Foerfarande foer stimulering av immunologiskt gensvar

Country Status (14)

Country Link
US (2) US5202119A (ja)
EP (1) EP0602050B1 (ja)
JP (1) JPH06508830A (ja)
AT (1) ATE152627T1 (ja)
AU (1) AU655059B2 (ja)
CA (1) CA2109705A1 (ja)
DE (1) DE69219607T2 (ja)
DK (1) DK0602050T3 (ja)
ES (1) ES2101106T3 (ja)
FI (1) FI935898A (ja)
GR (1) GR3024128T3 (ja)
NO (1) NO934851L (ja)
NZ (1) NZ243232A (ja)
WO (1) WO1993000110A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5744139A (en) * 1991-06-28 1998-04-28 University Of Tennessee Research Corporation Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
CA2132871A1 (en) * 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
AU6449894A (en) * 1993-03-19 1994-10-11 Michael M. Rothkopf Nutrient formulations and methods of treating malnutrition in aids
GB9310049D0 (en) * 1993-05-12 1993-06-30 Cancer Res Campaign Tech Growth factor effects
EP1238674B1 (en) * 1993-09-20 2005-06-08 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5661122A (en) * 1994-04-15 1997-08-26 Genentech, Inc. Treatment of congestive heart failure
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
WO1998016244A1 (fr) * 1996-10-16 1998-04-23 Sumitomo Pharmaceuticals Company, Limited Medicament utilise comme adjuvant dans l'hypothermie
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
EP1016414B1 (en) * 1998-12-17 2004-09-08 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
IL143866A0 (en) * 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AU2001246393A1 (en) * 2000-03-31 2001-10-08 Vaccine Chip Technology Aps Immunostimulating properties of a fragment of tgf-beta
US20030190322A1 (en) * 2000-03-31 2003-10-09 Peter Kaastrup Immunostimulating properties of a fragment of tgf-beta
EP1282437B1 (en) * 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
ES2331150T3 (es) * 2001-02-09 2009-12-22 Genentech, Inc. Metodos para identificar agonistas indirectos de igf-1.
FR2829498B1 (fr) * 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US7326417B2 (en) * 2001-09-11 2008-02-05 Merial Ltd. IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
CN101022820A (zh) * 2004-08-30 2007-08-22 特西卡股份有限公司 诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189426A (en) * 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4898830A (en) * 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US4621053A (en) * 1980-07-30 1986-11-04 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for the production of human peptide hormones
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
US4859600A (en) * 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US4863901A (en) * 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US4769361A (en) * 1986-08-07 1988-09-06 International Minerals & Chemical Corp. Method for purifying and isolating two ionic forms of somatomedin C
US4816439A (en) * 1987-03-27 1989-03-28 Nordiske Gentofte A/S The use of human growth hormone for the treatment of intoxicated individuals
US4833166A (en) * 1987-05-01 1989-05-23 Grosvenor Clark E Growth hormone releasing hormone complementary peptides
US5028591A (en) * 1987-09-14 1991-07-02 Pitman-Moore, Inc. Method for stimulating the immune system
US4837202A (en) * 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
JP2507106B2 (ja) * 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
US4939124A (en) * 1988-01-26 1990-07-03 Laboratorios Serono S.A. Treatment and diagnosis of dementia
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US5317012A (en) * 1991-10-04 1994-05-31 The University Of Tennessee Research Corporation Human growth hormone induced improvement in depressed T4/T8 ratio

Also Published As

Publication number Publication date
US5202119A (en) 1993-04-13
JPH06508830A (ja) 1994-10-06
ATE152627T1 (de) 1997-05-15
US5583109A (en) 1996-12-10
DE69219607T2 (de) 1997-09-04
DE69219607D1 (de) 1997-06-12
AU655059B2 (en) 1994-12-01
EP0602050A1 (en) 1994-06-22
ES2101106T3 (es) 1997-07-01
GR3024128T3 (en) 1997-10-31
CA2109705A1 (en) 1993-01-07
DK0602050T3 (da) 1997-06-02
NZ243232A (en) 1997-07-27
FI935898A (fi) 1993-12-28
NO934851L (no) 1994-02-25
EP0602050B1 (en) 1997-05-07
NO934851D0 (no) 1993-12-27
WO1993000110A1 (en) 1993-01-07
AU2252592A (en) 1993-01-25

Similar Documents

Publication Publication Date Title
FI935898A0 (fi) Foerfarande foer stimulering av immunologiskt gensvar
ES2189790T3 (es) Curacion de heridas y tratamiento de trastornos fibroticos mediante tgf beta-3.
AU2147192A (en) Method of stimulating immune response using growth hormone
ATE142110T1 (de) Impfstoff adjuvans
DE69201725D1 (de) Behandlungsmethoden für osteoporose.
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
ES2056822T3 (es) Agentes inmunoestimulantes.
IT8721616A0 (it) Procedimento per la preparazione dell'ormone della crescita umano
DE3851456D1 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
PL329077A1 (en) Method of treating cardiac insufficiency by means of endotelin antagonists
EP0254845A3 (en) Immune stimulation with chondroitin sulfate
ATE229981T1 (de) Glykolisierte cytokine
AU2085392A (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
EP0642333A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH IMMUNOLOGICAL DYSFUNCTION.
ATE59550T1 (de) Chlorpheniramine therapie.
IT8848243A0 (it) Il disturbo provocato da insetti metodo e composizione per evitare succhiatori di sangue
GR3018837T3 (en) Subcutaneous administration of human chorionic gonadotrophin.
IT8753187V0 (it) Dispositivo per la regolazione di un sedile per trattamenti odontoiatrici
SU1069818A1 (ru) Способ профилактики гриппа
GR3021983T3 (en) Cross-reactive influenza a immunization
ATE83931T1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
NZ215767A (en) Stimulating cashmere fibre growth on cashmere-producing goats by administration of melatonin
PT85076A (en) Method for the treatment of infections disease by administration of tumor necrosis factor-alpha
AU609435B2 (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
CA2133995A1 (en) Method and composition for the treatment of disorders involving immunological dysfunction